Dapagliflozin therapy in Type 2 Diabetes Mellitus patients fasting in the month of Ramadan.

Trial Profile

Dapagliflozin therapy in Type 2 Diabetes Mellitus patients fasting in the month of Ramadan.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Dapagliflozin (Primary) ; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 Primary endpoint (Mean change in body weight at week 6 (Ramadan fasting month) and week 12) has been met according to the results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes .
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top